Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at ...

Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the EvolutTM ...

Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...

"Medtronic announces two-year trial outcomes of Evolut TAVR" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in ...

Incidence of stroke within 72 hours after TAVI or before discharge, if sooner, came out a similar 2.1% with and 2.2% without ...

"Medtronic announces two-year trial outcomes of Evolut TAVR" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been ...

"Medtronic’s Evolut trial outcome could shift US TAVR market" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been ...

Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli. BioWorld MedTech Clinical Cardiovascular ...

In a notice posted to the agency’s website, the FDA noted that on January 30, 2025, Medtronic (MDT) Neurovascular sent all affected customers ...

Bengaluru: The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", following reports of the deaths of four patients.